Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hilary Thomas

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Anti-Cancer Drugs|December 13, 2006
Mode of action of the novel phenazine anticancer agents XR11576 and XR5944Louisa J Lewis, Prakash Mistry, Peter A Charlton, et al.
Drug Safety|March 1, 2005
Tibolone and endometrial cancer: a cohort and nested case-control study in the UKCorinne S de Vries, Susan E Bromley, Hilary Thomas, et al.
Complementary Therapies in Medicine|February 3, 2009
Integrated care: utilisation of complementary and alternative medicine within a conventional cancer treatment centreHeather Gage, Lesley Storey, Charlotte McDowell, et al.
BMJ Open|March 1, 2019
Protocol for a mixed-methods exploratory investigation of care following intensive care discharge: the REFLECT studySarah Vollam, Owen Gustafson, Lisa Hinton, et al.
Acta Oncologica (Stockholm, Sweden)|July 9, 2008
Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I studySvein Dueland, Steinar Aamdal, Michael J Lind, et al.
International Journal of Oncology|January 5, 2006
Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patientsMatthew P Cunningham, Sharadah Essapen, Hilary Thomas, et al.
International Journal of Oncology|July 13, 2005
Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancerMatthew P Cunningham, Sharadah Essapen, Hilary Thomas, et al.
International Journal of Oncology|January 14, 2004
The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parametersSharadah Essapen, Hilary Thomas, Margaret Green, et al.
International Journal of Cancer|April 4, 2003
Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapyHelmout Modjtahedi, David K Moscatello, Gary Box, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogeneSrinivasan Madhusudan, Ayala Tamir, Nicholas Bates, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Anti-Cancer Drugs|December 13, 2006
Mode of action of the novel phenazine anticancer agents XR11576 and XR5944Louisa J Lewis, Prakash Mistry, Peter A Charlton, et al.
Drug Safety|March 1, 2005
Tibolone and endometrial cancer: a cohort and nested case-control study in the UKCorinne S de Vries, Susan E Bromley, Hilary Thomas, et al.
Complementary Therapies in Medicine|February 3, 2009
Integrated care: utilisation of complementary and alternative medicine within a conventional cancer treatment centreHeather Gage, Lesley Storey, Charlotte McDowell, et al.
BMJ Open|March 1, 2019
Protocol for a mixed-methods exploratory investigation of care following intensive care discharge: the REFLECT studySarah Vollam, Owen Gustafson, Lisa Hinton, et al.
Acta Oncologica (Stockholm, Sweden)|July 9, 2008
Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I studySvein Dueland, Steinar Aamdal, Michael J Lind, et al.
International Journal of Oncology|January 5, 2006
Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patientsMatthew P Cunningham, Sharadah Essapen, Hilary Thomas, et al.
International Journal of Oncology|July 13, 2005
Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancerMatthew P Cunningham, Sharadah Essapen, Hilary Thomas, et al.
International Journal of Oncology|January 14, 2004
The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parametersSharadah Essapen, Hilary Thomas, Margaret Green, et al.
International Journal of Cancer|April 4, 2003
Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapyHelmout Modjtahedi, David K Moscatello, Gary Box, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogeneSrinivasan Madhusudan, Ayala Tamir, Nicholas Bates, et al.
Pageof 5